Praxis Precision Medicines 배당 및 자사주 매입

배당 기준 점검 0/6

Praxis Precision Medicines 배당금을 지급한 기록이 없습니다.

핵심 정보

n/a

배당 수익률

-13.2%

자사주 매입 수익률

총 주주 수익률	-13.2%
미래 배당 수익률	0%
배당 성장률	n/a
다음 배당 지급일	n/a
배당락일	n/a
주당 배당금	n/a
배당 성향	n/a

최근 배당 및 자사주 매입 업데이트

업데이트 없음

Recent updates

Seeking Alpha • Sep 12

Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)

Summary Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, underserved CNS markets with combined peak sales potential exceeding $15 billion. PRAX's $1.4 billion cash position supports a commercial buildout and reduces near-term capital market risk, with further upside from potential out-licensing and priority review vouchers. Despite the meteoric share run, PRAX retains significant upside, justifying a small investment, with covered calls offering an attractive entry strategy. Read the full article on Seeking Alpha

내러티브 업데이트 • Aug 22

PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk

Analysts have lifted the fair value estimate for Praxis Precision Medicines to $188 from $162, reflecting higher modeled revenue potential for its late stage epilepsy and essential tremor programs, partially offset by a higher discount rate, slightly lower profit margin assumptions, and a richer future P/E multiple. Analyst Commentary Recent Street research on Praxis Precision Medicines shows a wide spread in price targets and views, with several firms highlighting both upside scenarios around epilepsy and essential tremor assets and execution risks tied to clinical outcomes and commercialization.

내러티브 업데이트 • Aug 08

PRAX: Essential Tremor Launch Prospects Will Drive Future Upside Despite Seizure Trial Uncertainty

Praxis Precision Medicines enters this Narrative Update with the analyst price target higher in absolute dollar terms, supported by research that reflects revised fair value estimates, updated discount rates, refreshed revenue and margin assumptions, and a lower future P/E multiple in response to recent trial outcomes and pipeline commentary. Analyst Commentary Recent research on Praxis Precision Medicines presents a mixed picture, with several firms adjusting price targets and updating models after clinical readouts and management commentary.

내러티브 업데이트 • Jul 24

PRAX: Late Stage Neurology Pipeline Will Drive Future Upside Potential

The analyst price target for Praxis Precision Medicines moved from $843 to $1,201, with analysts pointing to potential approvals for ulixacaltamide and relutrigine, along with ongoing interest in the broader late stage pipeline as key reasons for their updated assumptions. Analyst Commentary Recent Street research on Praxis Precision Medicines reflects a wide range of views, but several bullish analysts highlight what they see as meaningful upside tied to the company’s late stage neurology pipeline.

내러티브 업데이트 • Jul 10

PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk

Analysts now place a $162.00 price target on Praxis Precision Medicines, adjusted from an earlier fair value estimate of about $85.76. This reflects updated views on discount rate, revenue growth potential, profit margins, and future P/E assumptions following recent trial outcomes and broader Street research.

내러티브 업데이트 • Jun 26

PRAX: Ulixacaltamide Tremor Opportunity Will Drive Future Upside Despite Vormatrigine Setback

Analysts have lifted their blended price target on Praxis Precision Medicines to about $618 from roughly $449, reflecting updated assumptions for ulixacaltamide's multi billion dollar sales potential in essential tremor and a lower, but still present, probability of success for vormatrigine after the POWER1 miss and POWER2 pause. Analyst Commentary Street research on Praxis Precision Medicines is split between enthusiasm for the ulixacaltamide opportunity and caution around execution risk after the POWER1 outcome for vormatrigine.

Seeking Alpha • Mar 04

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)

Summary Ulixacaltamide’s Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrigine (focal epilepsy) and relutrigine (SCN2A/SCN8A-DEEs). Vormatrigine must differentiate from Xcopri and XEN1101 in a highly competitive focal epilepsy market. Relutrigine showed promising seizure reduction in rare pediatric epilepsies but needs confirmation in larger pivotal trials. Praxis has $400M+ cash, funding operations into 2028, with key epilepsy trial readouts expected in 2H 2025. Read the full article on Seeking Alpha

Seeking Alpha • Dec 26

Praxis Precision Medicines: Multiple Potential Drivers

Summary Praxis Precision Medicines, Inc., a promising clinical stage biopharma concern, has seen significant stock gains in the second half of 2024. Analyst firms are quite bullish on the stock, with eight firms recently issuing Buy ratings and price targets ranging from $114 to $305 per share. The company has several potential drivers with its late-stage pipeline candidates and possesses a decent balance sheet. While the stock should only be considered by aggressive investors given its recent rally, I have taken a small position in PRAX stock via covered call orders. An analysis around Praxis Precision Medicines follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Oct 13

Praxis Precision Medicines: Great Price Movement, But Still Not Convinced

Summary Praxis Precision Medicines has shown impressive growth, but past trial failures and current risks warrant caution before investing. The lead candidate, Ulixacaltamide, is in a phase 3 trial for essential tremor, with results expected by the end of 2024. PRAX-628 shows promise for epilepsy, but the small patient cohort and competitive landscape raise concerns. Despite significant stock gains, I remain unconvinced and seek more data before making an investment decision. Read the full article on Seeking Alpha

지급의 안정성과 성장

배당 데이터 가져오는 중

안정적인 배당: 과거에 PRAX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: PRAX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

배당 수익률 vs 시장

Praxis Precision Medicines 배당 수익률 vs 시장

PRAX의 배당 수익률은 시장과 어떻게 비교되나요?
구분	배당 수익률
회사 (PRAX)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.1%
업계 평균 (Biotechs)	2.2%
분석가 예측 (PRAX) (최대 3년)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PRAX 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PRAX 의 배당 수익률을 평가할 수 없습니다.

주주 대상 이익 배당

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PRAX 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주 현금 배당

현금 흐름 범위: PRAX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

높은 배당을 제공하는 우량 기업 찾기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/09/14 02:26
종가	2026/09/14 00:00
수익	2026/06/30
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Praxis Precision Medicines, Inc.는 29명의 분석가가 다루고 있습니다. 이 중 18명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Brian Skorney	Baird
Joel Beatty	Baird
null null	Baird

Praxis Precision Medicines 배당 및 자사주 매입

배당 기준 점검 0/6

핵심 정보

최근 배당 및 자사주 매입 업데이트

Recent updates

Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)

PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk

Praxis Precision Medicines Gains FDA Breakthrough Status and Advances CNS Drug Development

PRAX: Essential Tremor Launch Prospects Will Drive Future Upside Despite Seizure Trial Uncertainty

Praxis Precision Medicines, Inc. to Report Q2, 2026 Results on Aug 06, 2026

PRAX: Late Stage Neurology Pipeline Will Drive Future Upside Potential

Consensus revenue estimates decrease by 23%

Consensus revenue estimates decrease by 14%

PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk

Praxis Precision Medicines Partners With Remagine Labs on Transdermal Essential Tremor Patch

Consensus revenue estimates decrease by 24%

FDA Extends Praxis Relutrigine Decision Timeline Following Major Data Amendment

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of Scn2a and Scn8a Developmental and Epileptic Encephalopathies

Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Microcap Growth Benchmark Index

Independent Director notifies of intention to sell stock

Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Microcap Index

PRAX: Ulixacaltamide Tremor Opportunity Will Drive Future Upside Despite Vormatrigine Setback

New minor risk - Share price stability

FDA Breakthrough Status for Praxis Precision Medicines Elsunersen in SCN2A-DEE Seizures

Praxis Precision Medicines Receives Fda Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with Scn2a Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

Praxis Precision Medicines Pauses Vormatrigine Trial to Reevaluate Epilepsy Pipeline After Mixed Results

Praxis Precision Medicines Reassesses Vormatrigine Program After Mixed POWER1 Trial Results

Praxis Precision Medicines Inc. Provides Vormatrigine Program Update

Consensus revenue estimates decrease by 30%

Praxis Precision Medicines, Inc. to Report Q1, 2026 Results on May 07, 2026

Praxis Precision Medicines, Inc., Annual General Meeting, Jun 10, 2026

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCI in Patients with Essential Tremor

Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy

Praxis Precision Medicines, Inc. Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

Price target increased by 7.8% to US$618

New major risk - Revenue size

Praxis Precision Medicines, Inc. to Report Q4, 2025 Results on Feb 19, 2026

Price target increased by 12% to US$513

Praxis Precision Medicines Appoints Orrin Devinsky as Head of Clinical Strategy

New major risk - Shareholder dilution

Praxis Precision Medicines, Inc. Announces Management Changes

Praxis Precision Medicines, Inc. has completed a Follow-on Equity Offering in the amount of $575.12 million.

Praxis Precision Medicines Announces U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Forecast to breakeven in 2028

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Price target increased by 15% to US$373

Praxis Precision Medicines, Inc. Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Praxis Precision Medicines, Inc. to Present Latest Preclinical and Clinical Advancements Across Leading Epilepsy Portfolio at the 2025 American Epilepsy Society Annual Meeting

General Counsel & Secretary notifies of intention to sell stock

New minor risk - Profitability

Third quarter 2025 earnings released: US$3.36 loss per share (vs US$2.75 loss in 3Q 2024)

Praxis Precision Medicines, Inc. Announces Accelerated Development Path for Relutrigine in Scn2a and Scn8a Dee Patients Following Positive Fda Feedback

New major risk - Shareholder dilution

Praxis Precision Medicines, Inc. has completed a Follow-on Equity Offering in the amount of $525.000118 million.

New major risk - Share price stability

Price target increased by 91% to US$190

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor

Independent Chairman of the Board exercised options to buy US$642k worth of stock.

Praxis Precision Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Praxis Precision Medicines, Inc. to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

Praxis Precision Medicines Announces Positive, Best-In-Disease Topline Results in Patients with Focal Onset Seizures from the Radiant Study of Vormatrigine

First half 2025 earnings released: US$6.60 loss per share (vs US$4.58 loss in 1H 2024)

Praxis Precision Medicines, Inc. to Report Q2, 2025 Results on Aug 04, 2025

Praxis Precision Medicines Receives Fda Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Consensus revenue estimates decrease by 19%

New major risk - Share price stability

New major risk - Financial position

First quarter 2025 earnings released: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)

Praxis Precision Medicines, Inc., Annual General Meeting, Jun 26, 2025

Consensus revenue estimates increase by 34%, EPS downgraded

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)

Price target decreased by 8.8% to US$146

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

Praxis Precision Medicines, Inc. Provides Update on Essential3

New minor risk - Share price stability

Praxis Precision Medicines: Multiple Potential Drivers

Price target increased by 12% to US$163

Praxis Precision Medicines, Inc. Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Consensus EPS estimates fall by 20%

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind